The BMAL1 Knockout HEK293T Polyclonal Cells product provides a genetically disrupted cell population for investigating circadian clock function. These polyclonal knockout cells, generated by CRISPR/Cas9-mediated gene disruption, target the BMAL1 (ARNTL) locus in the HEK293T human embryonic kidney epithelial cell line. The polyclonal format, derived from a pool of edited cells, captures heterogeneous mutational events while avoiding the bottlenecks of clonal selection, offering a more representative loss-of-function model. This product enables robust analysis of BMAL1-dependent transcriptional networks without the need for single-cell cloning, making it suitable for high-throughput screening and mechanistic studies in circadian biology.
HEK293T cells are a widely used derivative of the HEK293 line that stably expresses the SV40 large T antigen, which permits episomal replication of plasmids bearing the SV40 origin of replication. This feature enhances transient protein expression and viral production, establishing HEK293T as a versatile platform for studying gene function, signal transduction, and transcriptional regulation. The cell line??s human kidney epithelial origin provides a physiologically relevant background for examining metabolic and stress-related pathways, although the circadian clock machinery remains functional and responsive to entrainment cues in vitro.
BMAL1, also known as ARNTL, is a basic helix-loop-helix?CPAS transcription factor that forms a heterodimeric complex with CLOCK or its paralog NPAS2. This complex binds to E-box elements in the promoters of clock-controlled genes, driving their circadian expression. BMAL1 transcription is itself regulated by the opposing actions of retinoic acid receptor-related orphan receptor ?? (ROR??) and REV-ERB??, which compete for RORE motifs in the BMAL1 promoter. The CLOCK-BMAL1 complex activates downstream targets including the PER and CRY genes, whose protein products feedback to inhibit CLOCK-BMAL1 activity, forming the core negative feedback loop of the circadian oscillator. BMAL1 also regulates the expression of metabolic genes such as DBP, LDHB, G6PC, and c-MYC, linking the circadian clock to glucose metabolism, cell cycle control, and oncogenic signaling. The stability and activity of BMAL1 are further modulated by post-translational modifications involving CK1??/??, SIRT1, and ??-catenin interactions.
In the HEK293T context, BMAL1 knockout disrupts the heterodimerization with CLOCK, impairing transcription of clock-controlled genes and altering downstream processes such as cellular metabolism, proliferation, and oxidative stress responses. This model allows dissection of BMAL1-specific functions independent of other clock components, making it particularly valuable for studies on how circadian disruption contributes to metabolic syndrome, cancer, and cardiovascular disease. The polyclonal knockout population minimizes artifacts associated with clonal variation and provides a heterogeneous mutational landscape that more accurately reflects the genetic diversity encountered in population-level studies.
Researchers can employ these BMAL1 knockout cells in a broad array of experimental applications, including circadian expression profiling by RT-qPCR or RNA-seq, protein complex analysis via co-immunoprecipitation of BMAL1-CLOCK interactions, and functional assays using luciferase reporters driven by clock gene promoters. Metabolic assays measuring glucose uptake or lactate production, together with cell cycle analysis by flow cytometry, enable investigation of BMAL1??s role in connecting the circadian clock to cellular physiology. This product is an essential tool for drug target validation in chronotherapy and for dissecting the molecular mechanisms underlying circadian rhythm disorders. For further information, contact Ascent Research.
